• Home
  • NEW DAY MEDICINE
  • 3 (77) 2025
  • 92 -3 (77) 2025 - Musashayxov U.X., Boboev K.T. - ISCHEMIC DISEASE AND METABOLIC SYNDROME ON THE EXAMPLE OF THE STUDY OF POLYMORPHISM C58T SOD2 GENE

92 -3 (77) 2025 - Musashayxov U.X., Boboev K.T. - ISCHEMIC DISEASE AND METABOLIC SYNDROME ON THE EXAMPLE OF THE STUDY OF POLYMORPHISM C58T SOD2 GENE

ISCHEMIC DISEASE AND METABOLIC SYNDROME ON THE EXAMPLE OF THE STUDY OF POLYMORPHISM C58T SOD2 GENE

Musashayxov U.X. - Andijan State Medical Institute

Boboev K.T. - Republican Specialized Scientific and Practical Medical Hematology Center

Sattarov O.X. - Andijan State Medical Institute

Aripov O.A. - Center for the Development of Professional Qualifications of Medical Workers under the Ministry of Health of the Republic of Uzbekistan

Resume

The material for the molecular genetic study was the peripheral blood of 102 patients treated in the 1st Cardiology Department of the ADTI Clinic with a diagnosis of metabolic syndrome and coronary heart disease. Three subgroups were formed from these patients: - Subgroup 1: a group of patients with metabolic syndrome (MS) associated with coronary heart disease (CHD) (n=36); - Subgroup 2: a group of patients with MS not associated with CHD (n=32); - Subgroup 3: a group of patients with HF without MS (n=34).

Key words: C58T polymorphism, genetic marker SOD2, coronary heart disease, metabolic syndrome.

First page

530

Last page

534

For citation:Musashayxov U.X., Boboev K.T., Sattarov O.X., Aripov O.A. - ISCHEMIC DISEASE AND METABOLIC SYNDROME ON THE EXAMPLE OF THE STUDY OF POLYMORPHISM C58T SOD2 GENE//New Day in Medicine 3(77)2025 530-534 https://https://newdayworldmedicine.com/en/new_day_medicine/3-77-2025

List of References

  1. Boddu PC, Kadia T.M. Validation of the 2017 European LeukemiaNet classification for acute myeloid leukemia with NPM1 and FLT3-internal tandem duplication genotypes. Cancer. 2019;125(7):1091-100.
  2. Fazio F, Barberi W, Cazzaniga G. Efficacy of imatinib and chemotherapy in a pediatric patient with Philadelphia-like acute lymphoblastic leukemia with EBF1- PDGFRB fusion transcript. Leuk Lymphoma. 2020; 61(2):469-472.
  3. Fernandez-Pol S, Ma L, Ohgami RS, et al. Immunohistochemistry for p53 is a useful tool to identify cases of acute myeloid leukemia with myelodysplasia-related changes that are TP53 mutated, have complex karyotype, and have poor prognosis. Mod Pathol. 2017; 30: 382-392.
  4. Hou HA, Chou WC, Kuo YY, et al. TP53 mutations in de novo acute myeloid leukemia patients: longitudinal follow-ups show the mutation is stable during disease evolution. Blood Cancer J. 2015;5:e331
  5. Krauth MT, Eder C, Alpermann T, et al. High number of additional genetic lesions in acute myeloid leukemia with t(8;21)/RUNX1-RUNX1T1: frequency and impact on clinical outcome. Leukemia. 2014; 28:1449-1458.
  6. Lai C, Doucette K, Norsworthy K. Recent drug approvals for acute myeloid leukemia. J Hematol Oncol. 2019;12(1):100.
  7. Ma L, Li X, Zhang J, et al. [Acquired aplastic anemia developing myelodysplastic syndrome/acute myeloid leukemia: clinical analysis of nineteen patients and literatures review]. Zhonghua Xue Ye Xue Za Zhi. 2015; 36:216-220.
  8. Mansoori B., Mohammadi A., Davudian S., Shirjang S., Baradaran B. The Different Mechanisms of Cancer Drug Resistance: A Brief Review. Adv. Pharm. Bull. 2017;7:339-348. doi: 10.15171/apb.2017.041.

    file

    download